Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The Journal of the Royal Society for the Promotion of Health
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Web of Science (3)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Siddiqui, E.
Right arrow Articles by Gelister, J.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Understanding prostate cancer

Emad Siddiqui, BSc, MBBS, MRCS

Department of Surgery and Department of Clinical Biochemistry, Royal Free and University College Medical School, Royal Free Campus, London NW3 2QG, England, and Department of Urology, Barnet and Chase Farm Hospital, Enfield EN2 8JL, England

Faiz H Mumtaz, MD, FRCS

Department of Urology, Chase Farm Hospital, Enfield EN2 8JL, England

James Gelister, FRCS

Department of Urology, Chase Farm Hospital, Enfield EN2 8JL, England

Prostate cancer is the second most common cancer affecting men in Europe and the USA. The incidence of prostate cancer has risen by 60-75% in the Western world in the last 15 years. One in twelve men over the age of 60 develop prostate cancer and this figure is expected to rise to three in twelve in the next 20 years. Early prostate cancer often does not cause symptoms. However, patients may present with lower urinary tract symptoms (LUTS) and therefore, such patients should be investigated. Effective treatment in the form of surgery and radiotherapy is available for individuals with localised disease, and the effectiveness of different combination therapy is being assessed to improve the outcome further.

Approximately 20% of the patients have metastatic disease on presentation. The mainstay of treatment for these patients is androgen ablation therapy; however patients on this regime eventually relapse and develop an androgen independent tumour. This aggressive stage of the disease carries a high morbidity and mortality. At present the treatment for such hormone refractory prostate cancer is inadequate and the desperate search for alternative forms of therapy continues.

Key Words: Hormone ablation therapy • prostate cancer • prostate-specific antigen • radical prostatectomy • transrectal ultrasound-guided biopsy

The Journal of the Royal Society for the Promotion of Health, Vol. 124, No. 5, 219-221 (2004)
DOI: 10.1177/146642400412400518
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?